Spoke to MSB this am to get some answers investors need to know:...

Spoke to MSB this am to get some answers investors need to know: CHF ph 3, first of all its going ahead, the reason for this is it,s very complex and as you would know MSB is meticulous in anything they enter into, So the reason for delay sits both with Teva msb thats the " cause ". I was told ph.3 would start very soon after I suggested would it be in the 3rd Q calender year and that was agreed to...Fast track has been with the FDA for a decade, Congress has passed new laws and its called " break thru therapy status " and no MSB have no applications in the conduit to the FDA and never have so none have been rejected. Strategy is certainly on track one other point that was mentioned was MSB are right on top of the "fast tracking of stem cell therapy"in Japan and of course we have patents locked up there it may be our first winner .. Cheers VIN